Tiancong: Full Subsidiary's Drug Registration Application Accepted

Tiankang Announcement: Tiankang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the "Acceptance Notice" of the domestic production drug registration for Sufentanil Mesylate Tablets issued by the National Medical Products Administration. This drug is mainly used for the treatment of adult-onset Parkinson's disease patients, as an adjunct therapy in combination with stable doses of levodopa alone or in combination with other PD treatments, for patients with fluctuations in the middle and late stages.